This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
by Zacks Equity Research
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
Bull or Bear: Your Investment Strategy for 2019
by Sejuti Banerjea
Whether you're a bull or a bear, it may be a good idea to go defensive about now.
Vertex Joins Forces With Arbor to Build Gene-Editing Therapies
by Zacks Equity Research
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
Emergent (EBS) Files Application for Emergency Use of NuThrax
by Zacks Equity Research
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
Ring in 2019 With These 7 Solid Growth Stocks in Your Kitty
by Madhura Bhattacharyya
Let's take a look at seven growth stocks that are poised to offer impressive returns in 2019.
Four Biotech Stocks That Popped More Than 50% in 2018
by Zacks Equity Research
The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
4 Stocks That Had Massive Earnings Surprises in 2018
by Ankita Gupta
Given the market volatility, let's take a look at four stocks that survived the onslaught and even surpassed market expectations.
Inovio (INO) to Receive Milestone Payment From AstraZeneca
by Zacks Equity Research
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Amgen's BiTE Immunotherapies Show Promise in Early Studies
by Zacks Equity Research
Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA
Company News For Dec 4, 2018
by Zacks Equity Research
Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT
FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate
by Zacks Equity Research
The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.
Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
by Zacks Equity Research
Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
5 Stocks With Recent Price Strength to Strengthen Portfolio
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?
by Zacks Equity Research
Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%
by Zacks Equity Research
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
Vanda Pharmaceuticals (VNDA) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 1900.00% and 0.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Menlo Stock Plunges on Phase II Chronic Cough Study Failure
by Zacks Equity Research
Menlo Therapeutics' (MNLO) sole pipeline candidate, serlopitant, fails to meet endpoint in a phase II study in refractory chronic cough patients. Study to be terminated.
Vanda Pharmaceuticals (VNDA) Catches Eye: Stock Jumps 8.7%
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.
Zacks.com highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon
by Zacks Equity Research
Zacks.com highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon
Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.